This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
News & Press: COVID-19

Monitoring the Immune System to Fight COVID-19: CD4 Status, Lymphopenia, and Infectivity

Tuesday, April 28, 2020   (0 Comments)

Learn about specific, ongoing clinical research in SARS-CoV-2 hotspots and the application of flow cytometry to identify biomarkers for COVID-19 severity
Join a discussion on the implications of these findings as they relate to the international guidance for COVID-19 disease treatment and prevention in persons living with HIV.

This webinar will last for approximately 60 minutes.

Speaker bios

Andrea Cossarizza, M.D., Ph.D.
University of Modena and Reggio Emilia School of Medicine
Modena, Italy

Dr. Cossarizza completed his M.D. degree at the University of Padova in Italy before receiving a Ph.D. in oncology from the University of Modena and Reggio Emilia (UNIMORE) and the University of Bologna, also in Italy. After specializing in clinical pathology at UNIMORE, he obtained an associate professorship there and, in 2010, he became a full professor in pathology and immunology. At present, he is vice-dean of the School of Medicine at UNIMORE and director of the School of Clinical Pathology. In 2016, he was elected president of the International Society for Advancement of Cytometry (ISAC). His primary research focus is identifying the molecular and cellular basis for the involvement of the immune system in diseases and infections, including HIV/AIDS and sepsis, as well as its role in pathophysiological conditions related to aging and neurodegeneration. Dr. Cossarizza has notable experience in the development and use of new flow cytometry approaches in immunological research, has published more than 330 papers in peer-reviewed journals, and is a member of several editorial boards of international journals. From the first moments of the pandemic, he has been studying immunological changes in COVID-19 patients and the efficacy of novel immune therapies.

Maurice O’Gorman, Ph.D., M.B.A., (D)ABMLI
Children's Hospital Los Angeles,
Los Angeles, CA

Dr. O’Gorman earned his Master’s and Ph.D. at the University of British Columbia before completing a postdoctoral fellowship at the University of North Carolina at Chapel Hill. He then joined the faculty at the Feinberg School of Medicine at Northwestern University, during which time he earned his MBA from Northwestern and served as vice chair of Pathology and Laboratory Medicine and director of Diagnostic Immunology and Flow Cytometry at Children’s Memorial Hospital in Chicago. He is currently chief of laboratory medicine, as well as director of the Clinical Lab and the Diagnostic Immunology and Flow Cytometry Laboratory at Children’s Hospital Los Angeles, and a professor of pathology and pediatrics at the Keck School of Medicine of the University of Southern California. Dr. O’Gorman’s research interests include immunopathogenesis of immune system–related disorders, investigation of immune mechanisms of immune suppression withdrawal in liver transplant patients, and the development of novel immune-related diagnostic laboratory tests. Additionally, he provides ad hoc reviews for multiple journals, including Cytometry, Journal of Leukocyte Biology, Journal of Immunological Methods, Clinical and Diagnostic Laboratory Immunology, and Archives of Pathology & Laboratory Medicine.

Lishomwa (Lish) Ndhlovu, M.D., Ph.D.
Weill Cornell Medicine
New York, NY

Dr. Ndhlovu is a professor of immunology at Weill Cornell Medicine in New York and principal investigator of the HIV and Emerging Pathogens Immunopathogenesis Laboratory in the Division of Infectious Diseases, also at Weill Cornell. A translational immunologist, he leads a research team dedicated to confronting the challenges of HIV and aging, with an emphasis on limiting disease complications and developing curative strategies. His program is now bringing the same urgency and focus to the COVID-19 pandemic, using both single-cell and epigenetic approaches to resolve molecular mechanisms regulating viral entry of SARS-CoV-2 infection across different tissues and cell types. His work seeks to identify therapeutic host targets and future therapies that reduce morbidity and mortality, and relieve the burden of this disease on society. Dr. Ndhlovu completed his undergraduate degree at the University of Zambia, his medical training at the University of Zambia Medical School, and his doctorate at Tohoku University School of Medicine in Japan.

Sean Sanders, Ph.D.
Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently, Dr. Sanders is the Director and Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.